Significantly high AGR2 expression was observed in PTEN, KRAS (the commonest mutations seen in endometrioid cancers) mutated cancers compared with wild type cancers (p = 5.29E-8 and p = 4.74E-4 respectively, results not shown), and contrastingly low AGR2 levels were seen in TP53 mutated cancers (commonest mutations seen in high grade/ type 2 cancers) compared with the wild type cancers in the TCGA dataset (p = 9.98E-8, results not shown). The gene discussed is AGR2; the disease is cancer.